

Freedom of Information Act Request

Under the Freedom of Information Act, I would like to request the following information:

1. For the financial years 2022/23, 2023/24 and current YTD, how many referrals have you received for wet AMD, diabetic macular oedema and retinal vein occlusion (Anti VEGf services) or perhaps referred to as medical retina?

Referral detail available from April 2023 into the MR Service

April 2023-March 24:

- Accepted 546
- Rejected 64

April 2024 – YTD

- Accepted 360
- Rejected 45

AMD Referral Data from - April 2024 – YTD

- Accepted 550
- 2. For the financial years 2022/23, 2023/24 and current YTD, how many referrals have you rejected as unsuitable or undeliverable by your Trust?

Referral detail available from April 2023 into the MR Service

April 2023-March 24:

- Accepted 546
- Rejected 64

April 2024 – YTD

- Accepted 360
- Rejected 45

Unsuitable: usually non-referable DR and the patient is already under DESP

Undeliverable: when it is for VR - that service is at RHH

3. For the financial years 2022/23, 2023/24 and current YTD, how many referrals have you received, triaged, booked and completed first assessment and treatment within the 2 week RTT advised by NICE and the college of ophthalmologists? We are looking for your Trust performance data against the 14 day standard as a % by month for the periods - 2023/24 and 2024/25

Recent IVT Tracker implemented to capture exact Referral data. Unable to provide data at this time

4. How many patients are currently on a waiting list for an appointment for first assessment and or treatment? How many have breached the 2 week RTT?

None.

The Service does not have any patients awaiting 1st appointment.

Recent IVT Tracker implemented to capture exact RTT data. Unable to provide data at this time

5. How many patients are currently on a waiting list for a follow up appointment and treatment? How many of these have waited longer than the requested call back date stated as an outcome of their last assessment? (Ie overdue?) How many are overdue by more than one month? (We exclude from this any patients who have cancelled / DNA'd or are unable to attend an appointment that has been offered)



6. Which drugs are your preferred for a new patient? Which drugs do you still use for follow-up patients?

Vabysmo first line for wet AMD, and Eylea first line for DMO. RVO is 50/50.

7. Does your trust follow a see and treat "one stop" clinic format?

Where possible the service inject new wet AMD on the day.

8. Does your trust follow treat and extend protocols where clinically appropriate?

Yes				

9. How many patients have you certificated as sight impaired or severely sight impaired in the FYs 2022/23, 2023/24 and year to date due to Wet AMD?

TBC



